Celgene Corporation Reviews 2004 Achievements and Announces 2005 Financial Outlook
Celgene Corporation today reviewed its clinical and commercial progress in 2004 and provided its initial outlook for 2005 at the J.P. Morgan 23rd Annual Healthcare Conference.
In 2004, Celgene achieved outstanding results in its commercial operations, financial performance, and clinical performance advancing REVLIMID(R) in key clinical trials.
The growing success of the Company's commercial franchise was demonstrated by the continued acceleration of product revenue and profit growth that reflects the positive impact of new clinical data on Celgene products presented at major international medical meetings such as American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH), as well as an expanding volume of multiple peer-reviewed articles in major publications such as The Journal of Clinical Oncology and The New England Journal of Medicine.
Celgene intends to disseminate its 2004 full-year financial results on January 27, 2005.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.